1.
Administration of Tranexamic Acid in Proximal Humeral Fractures
Yang YY, Qin H, Zheng X, Hu B, Zhang M, Ma T
Indian journal of orthopaedics. 2020;54(Suppl 2):277-282
Abstract
INTRODUCTION This study aimed to analyze the efficacy of intravenous administration of tranexamic acid in complex proximal humeral fractures. MATERIALS AND METHODS Sixty-seven patients with displaced 3 and 4 part proximal humerus fractures were randomized into the control (nā=ā33) and TXA (nā=ā34) groups. Fifteen minutes before the skin incision, 15 mg/kg body weight of 0.9% sodium chloride solution or TXA was injected intravenously. Open reduction and internal fixation was conducted through a deltoid-pectoral approach with fixed angle locked plating (PHILOS) for all the patients. The patients were followed up 2 months after surgery. Total blood loss, blood test results, blood transfusion rate, and wound complications were analyzed between the two groups. RESULTS Significant differences were observed in intraoperative blood loss and postoperative blood loss during the first 24 h between the two groups. There were no significant differences in postoperative blood loss during the second 24 h, wound complication rates, blood transfusion rate and adverse side effects. And thromboembolic events related with the application of TXA were not noted in the TXA group. CONCLUSION Preoperative administration of tranexamic acid could reduce intraoperative and postoperative blood loss in patients with complex proximal humeral fractures. LEVEL OF EVIDENCE II, prospective comparative study.
2.
Antepartum immunoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single-centre randomized study
Yuan J, Lin J, Xu A, Li H, Hu B, Chen J, Yao J, Dong H, Jiang M
Journal of Viral Hepatitis. 2006;13((9):):597-604.
Abstract
To investigate the efficacy of antepartum administration of three doses of hepatitis B immunoglobulin (HBIg), currently being used in China, 250 pregnant women who were seropositive for hepatitis B e antigen (HBeAg) were randomly divided into study (117 cases) and control groups (133 cases). Subjects in the study group received HBIg 400 IU intramuscularly once a month at the third, second and first month before delivery; subjects in the control group received no antepartum treatment. All neonates received passive-active immunization after birth. The maternal hepatitis B virus (HBV) markers, hepatitis B surface antigen (HBsAg) titres and HBV deoxyribonucleic acid (DNA) levels were measured at week 28 of gestation (before the antepartum treatment) and at labour; the neonatal serum HBV markers were detected at birth and at 12 months after birth. No side-effects were found in any of the women or their neonates. No statistical differences were seen between the maternal HBsAg and HBV DNA levels of the study and control groups at labour nor the protective efficacy rates of postnatal immunoprophylaxis at 12 months after birth (P > 0. 05, respectively). To conclude, antepartum administration of three doses of HBIg for the HBeAg-positive women is inefficacious.